Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database-Reference-Cited by-同舟云学术

Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database

Published:2023-06 Issue: Volume:200 Page:110685
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Lo Shih-Chang^ORCID,Kornelius Edy,Liao Pei-Lun^ORCID,Huang Jing-Yang^ORCID,Yang Yi-Sun,Huang Chien-Ning

Funder

Chung Shan Medical University Hospital

National Health Research Institutes

Ministry of Health and Welfare

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference28 articles.

1. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res Clin Pract,2022

2. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Sarwar;Lancet,2010

3. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

4. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial;Dormandy;Lancet,2005

5. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack;Kernan;N Engl J Med,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database;Journal of Diabetes Research;2024-05-30

2. Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial;Diabetes, Obesity and Metabolism;2024-05-03

3. Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database;Diabetes, Obesity and Metabolism;2024-04

4. A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin;Diabetes, Obesity and Metabolism;2024-02-29

5. In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome;Diabetes, Obesity and Metabolism;2023-08-03